Diabetes Type 2 Clinical Trial
Official title:
The Effect of Aerobic Interval Training on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction
The aim of the study is to compare the effects of aerobic interval training and the IDF
recommendations on physical activity on cardiac function and CV risk factors in patients with
diabetes. The hypothesis is that AIT more than MCT, will improve myocardial dysfunction in
patients with subclinical LV disease, improve both endothelial function and VO2max and thus
reducing CV risk factors and CV disease. HbA1c will be more stable.
The aims of this study are to address the exercise prescription recommendations for patients
with (T2DM) who have subclinical heart disease. The prescription recommendations will be
assessed by randomising T2DM patients with subclinical heart disease to one of the following
2 groups for 3 months followed by a 9 month home-based program:
Moderate Intensity Exercise Group (ME). Home exercise equivalent to the present exercise
recommendations of the International Diabetes Federation.
Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved
through high-intensity interval training.
The investigators primary hypotheses are that in patients with type 2 diabetes and
subclinical heart disease:
Moderate Intensity Exercise will:
Not significantly improve myocardial function compared to controls,
Despite significant improvement (compared to controls) in:
Glycaemic control (HbA1c) Cardiorespiratory fitness (VO2max) Body composition (DXA)
Aerobic Interval Training Group will:
Significantly improve myocardial function compared to controls,
Significantly improve (compared to moderate intensity exercise group):
Glycaemic control (HbA1c) Cardiorespiratory fitness (VO2max) Body composition (DXA)
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Active, not recruiting |
NCT04954313 -
Baseline Oral Health Study: UnCoVer the Connections to General Health
|
Phase 4 | |
| Not yet recruiting |
NCT06437782 -
Exploration of Health Literacy in Diabetes in Reunion Island and France
|
||
| Completed |
NCT01354925 -
Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan
|
Phase 4 | |
| Completed |
NCT00997282 -
A Study of OPC-262 in Patients With Type 2 Diabetes
|
Phase 2/Phase 3 | |
| Completed |
NCT00637546 -
Gait and Balance of Diabetes Type 2 Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00464880 -
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02057497 -
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
|
N/A | |
| Active, not recruiting |
NCT05014204 -
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
|
N/A | |
| Recruiting |
NCT03662217 -
Personalized Nutrition for Diabetes Type 2
|
N/A | |
| Completed |
NCT04276051 -
Cryovagotomy Diabetes Trial
|
N/A | |
| Completed |
NCT02569684 -
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
|
N/A | |
| Active, not recruiting |
NCT01933529 -
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
|
Phase 2 | |
| Terminated |
NCT01722474 -
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
|
N/A | |
| Completed |
NCT00977262 -
Postprandial Inflammation and Fatty Acids
|
N/A | |
| Completed |
NCT00518427 -
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
|
Phase 4 | |
| Recruiting |
NCT05378620 -
Project Dulce for Filipino-Americans With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT03834207 -
A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy
|
N/A | |
| Active, not recruiting |
NCT05228067 -
Enhancing Brain Health by tDCS in Persons With Overweight and Obesity
|
N/A | |
| Active, not recruiting |
NCT05689684 -
Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes
|
N/A |